BioWorld Asia

Feb. 13, 2002

NeuroSearch, Ingelheim Enter $80M Alliance Around NS2330

Shares in NeuroSearch A/S surged more than 50 percent Friday on news of its largest ever deal, a US$80 million pact with Boehringer Ingelheim GmbH to develop its candidate Alzheimer’s and Parkinson’s drug, NS2330. (BioWorld International) Read More

Irish Government Backs EUR15M Biotech Life Sciences Seed Fund

Genetic Tests Predict Cancer Risks, Melanoma Study Shows

EU Officials Want Legislation Covering Tissue, Cell Implants

Proteom Raises £3M To Further Work Around Protein Interactions

Other News To Note

Transgene Says Restructuring In Place, Products Moving Along

Scancell Partners Antibody Drug In Asia With Korean Company

Metabolic Eyeing Phase IIb Trial In Obesity After Positive IIa Study

Today's news in brief

BioWorld

BioWorld briefs for Dec. 19, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 19, 2025.

Apollo’s APL-4098 shows potent antileukemic effects

BioWorld Science

Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.

Illustration of brain with electrical activity background

ABS-1230 controls seizures in KCNT1-driven severe epilepsy

BioWorld Science

Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...

ASH 2025: Ianalumab data offer break from chronic ITP therapy

BioWorld

Novartis AG’s monoclonal antibody, ianalumab (VAY-736), when added to standard-of-care eltrombopag, extended disease control of primary immune thrombocytopenia...